2
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Disposition of patients with coronavirus disease 2019 (COVID-19) whose respiratory specimens remain positive for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) by polymerase chain reaction assay (PCR)

      article-commentary
      , DO, ScM 1 , 2
      Infection Control and Hospital Epidemiology
      Cambridge University Press

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Patients with coronavirus disease 2019 (COVID-19) infection may respiratory tract specimens positive for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) for several days while in isolation precautions or for several weeks after removal from isolation precautions. This situation creates a dilemma for infection control staff in acute and chronic healthcare settings and for public health officials. Potentially keeping such patients in isolation precautions beyond the period when they are no longer infectious leads to unnecessary actions and consequences: personal protective equipment use; single-patient room occupancy; repeat PCR testing; social isolation; delay from reentering the work force, particularly problematic for healthcare workers and essential civil servants; and redistribution of infection control and public health human capital assigned to track the status of such individuals. These downstream effects have unequivocal and profound economic impact that may be avoidable. Can patients in isolation precautions with COVID-19 infection be removed from precautions prior to current guidelines? Yes isolation precautions can be removed after 9 days from symptom onset or after 9 days from the first positive SARS-CoV-2 PCR test of a respiratory specimen in asymptomatic individuals. No reports, known to this author, of viable SARS-CoV-2 detection in respiratory tract specimens collected beyond 9 days after symptom onset have been published. 1-3 As with other emerging viral infections, 4 patients with a high SARS-CoV-2 PCR cycle threshold (eg, cycle threshold ≥34 in one study 5 or >24 in another 3 ) have not been found to have live virus in their respiratory secretions. Similar findings at CDC have been found with a cycle threshold >33 with the N1 amplification target. 6 A study in Taiwan 7 included 100 patients with COVID-19 infection and their 2,761 close contacts (face-to-face contact for >15 minutes with a confirmed COVID-19 patient). SARS-CoV-2 PCR testing was performed on all symptomatic contacts (ie, contacts with fever, cough, or other respiratory symptoms). SARS-CoV-2 polymerase chain reaction (PCR) testing was also performed on all household and hospital contacts, regardless of symptoms, when they were initially assessed. If PCR testing was negative, they were tested again if they developed such symptoms during the 14 days after their initial contact with a case patient. The investigators found no secondary COVID-19 infections among 852 contacts exposed to infected cases if the exposure occurred after the initial 5 days of symptom onset. These epidemiologic data support the aforementioned laboratory data. Are there exceptions? Yes, severely immunocompromised patients may be an exception. Based on data from other viral infections, 8,9 patients with COVID-19 infection who are severely immunocompromised may have prolonged shedding of live virus. Thus, decisions regarding discontinuing isolation precautions for severely immunocompromised patients, or possibly those who are otherwise critically ill with COVID-19 infection, should be based on a high SARS-CoV-2 PCR cycle threshold. 3,5,6 Importantly, the cycle threshold varies depending on the PCR protocol and amplification target used in the PCR assay. Such patients, and all others, should continue to follow CDC and local health official guidance regarding continued source control after hospital discharge (ie, mask use and hand hygiene), as well as social distancing. Are patients infectious if they previously had a COVID-19 infection, met criteria for removal from isolation precautions, and they have SARS-CoV-2 PCR-positive respiratory tract specimens over the next several weeks? In most cases, no. The Korean CDC studied 285 SARS-CoV-2 PCR-positive patients after removal from isolation precautions and an average of 45 days after symptom onset (range, 8–82 days); 126 still had some COVID-19 related symptoms. 10 All 285 were seropositive. SARS-CoV-2 culture was negative in 108 patients who had such cultures performed. These 285 patients had 790 contacts, including 351 family members. Contacts were monitored for minimum of 14 days each. SARS-CoV-2 PCR testing of contacts was performed if they became symptomatic (ie, either temperature ≥37.5°C, sore throat, cough, etc); otherwise, PCR testing was done on day 13 after the exposure if the contact was a healthcare worker or household member (YJ Choe, personal communication). There was no evidence of COVID-19 transmission to these contacts: 27 of the 790 contacts were previously SARS-CoV-2 PCR-positive, and 3 newly SARS-CoV-2 PCR-positive contacts had other high-risk exposures. Are there exceptions? Yes, severely immunocompromised patients or reinfection in those patients or others may be exceptions. For severely immunocompromised patients or if otherwise in question, the SARS-CoV-2 cycle threshold will assist in determining infectivity. Reinfection with SARS-CoV-2 remains an open question. At this time, it is unclear when to assess patients for possible reinfection and the risk of disease transmission if that occurs. After COVID-19 infection, SARS-CoV-2 IgG antibodies remain significantly elevated for at least 7 weeks in most cases 11 ; however, 6% of patients with relatively mild COVID-19 infection have been found to recover without detectable neutralizing antibodies. 12 Neutralizing antibodies can be detected for 2 years in ~90% SARS-infected patients. 13 However, antibody levels drop after 2–3 years in patients who recovered from SARS and MERS-CoV infections. 14 Reinfection from the same genotype of human coronaviruses can occur within months to a year later. 15,16 Since SARS-CoV-2 neutralizing antibodies are protective in rhesus macaques, 17,18 and if durability of these antibodies is similar to that of patients who recovered from SARS and MERS-CoV infections, SARS-CoV-2 PCR positivity beyond 9 days from symptom onset is unlikely to reflect reinfection over the ensuing months in seropositive immunocompetent patients. However, if neutralizing antibody levels wane after several months to a year, then SARS-CoV-2 PCR positivity may reflect reinfection, and the SARS-CoV-2 cycle threshold will assist in determining the need for isolation precautions or quarantine. Based on the aforementioned data, patients with COVID-19 infection who are beyond 9 days from symptom onset or beyond 9 days from the first SARS-CoV-2 PCR-positive testing of a respiratory specimen in asymptomatic patients, should not undergo repeat SARS-CoV-2 PCR testing unless they are presenting several months after symptom onset or asymptomatic detection (ie, long enough time for possible reinfection), or they are otherwise severely immunocompromised. The patient should not be placed back in isolation precautions unless severely immunocompromised. Immunocompetent patients with a SARS-CoV-2 PCR-positive respiratory specimen obtained >9 days after symptom onset, or first positive testing for asymptomatic patients, should be allowed to have procedures, surgical or otherwise, or to undergo testing as clinically indicated without the precautions used for patients with active COVID-19 infection unless they are presenting several months after either symptom onset or their initial positive SARS-CoV-2 PCR testing, or they are severely immunocompromised. In such cases, determination of SARS-CoV-2 cycle threshold will assist in decisions regarding infection control precautions.

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Virological assessment of hospitalized patients with COVID-2019

          Coronavirus disease 2019 (COVID-19) is an acute infection of the respiratory tract that emerged in late 20191,2. Initial outbreaks in China involved 13.8% of cases with severe courses, and 6.1% of cases with critical courses3. This severe presentation may result from the virus using a virus receptor that is expressed predominantly in the lung2,4; the same receptor tropism is thought to have determined the pathogenicity-but also aided in the control-of severe acute respiratory syndrome (SARS) in 20035. However, there are reports of cases of COVID-19 in which the patient shows mild upper respiratory tract symptoms, which suggests the potential for pre- or oligosymptomatic transmission6-8. There is an urgent need for information on virus replication, immunity and infectivity in specific sites of the body. Here we report a detailed virological analysis of nine cases of COVID-19 that provides proof of active virus replication in tissues of the upper respiratory tract. Pharyngeal virus shedding was very high during the first week of symptoms, with a peak at 7.11 × 108 RNA copies per throat swab on day 4. Infectious virus was readily isolated from samples derived from the throat or lung, but not from stool samples-in spite of high concentrations of virus RNA. Blood and urine samples never yielded virus. Active replication in the throat was confirmed by the presence of viral replicative RNA intermediates in the throat samples. We consistently detected sequence-distinct virus populations in throat and lung samples from one patient, proving independent replication. The shedding of viral RNA from sputum outlasted the end of symptoms. Seroconversion occurred after 7 days in 50% of patients (and by day 14 in all patients), but was not followed by a rapid decline in viral load. COVID-19 can present as a mild illness of the upper respiratory tract. The confirmation of active virus replication in the upper respiratory tract has implications for the containment of COVID-19.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Predicting infectious SARS-CoV-2 from diagnostic samples

            Abstract Background RT-PCR has become the primary method to diagnose viral diseases, including SARS-CoV-2. RT-PCR detects RNA, not infectious virus, thus its ability to determine duration of infectivity of patients is limited. Infectivity is a critical determinant in informing public health guidelines/interventions. Our goal was to determine the relationship between E gene SARS-CoV-2 RT-PCR cycle threshold (Ct) values from respiratory samples, symptom onset to test (STT) and infectivity in cell culture. Methods In this retrospective cross-sectional study, we took SARS-CoV-2 RT-PCR confirmed positive samples and determined their ability to infect Vero cell lines. Results Ninety RT-PCR SARS-CoV-2 positive samples were incubated on Vero cells. Twenty-six samples (28.9%) demonstrated viral growth. Median TCID50/ml was 1780 (282-8511). There was no growth in samples with a Ct > 24 or STT > 8 days. Multivariate logistic regression using positive viral culture as a binary predictor variable, STT and Ct demonstrated an odds ratio for positive viral culture of 0.64 (95% CI 0.49-0.84, p 24. Conclusions SARS-CoV-2 Vero cell infectivity was only observed for RT-PCR Ct 24 and duration of symptoms >8 days may be low. This information can inform public health policy and guide clinical, infection control and occupational health decisions. Further studies of larger size are needed.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              DNA vaccine protection against SARS-CoV-2 in rhesus macaques

              The global COVID-19 pandemic caused by the SARS-CoV-2 virus has made the development of a vaccine a top biomedical priority. In this study, we developed a series of DNA vaccine candidates expressing different forms of the SARS-CoV-2 Spike (S) protein and evaluated them in 35 rhesus macaques. Vaccinated animals developed humoral and cellular immune responses, including neutralizing antibody titers comparable to those found in convalescent humans and macaques infected with SARS-CoV-2. Following vaccination, all animals were challenged with SARS-CoV-2, and the vaccine encoding the full-length S protein resulted in >3.1 and >3.7 log10 reductions in median viral loads in bronchoalveolar lavage and nasal mucosa, respectively, as compared with sham controls. Vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate vaccine protection against SARS-CoV-2 in nonhuman primates.
                Bookmark

                Author and article information

                Journal
                Infect Control Hosp Epidemiol
                Infect Control Hosp Epidemiol
                ICE
                Infection Control and Hospital Epidemiology
                Cambridge University Press (New York, USA )
                0899-823X
                1559-6834
                10 June 2020
                : 1-2
                Affiliations
                [1 ]Division of Infectious Diseases, Department of Medicine, Warren Alpert Medical School of Brown University , Providence, Rhode Island
                [2 ]Department of Epidemiology and Infection Control, Rhode Island Hospital , Providence, Rhode Island
                Author notes
                Author for correspondence: Leonard Mermel, E-mail: lmermel@ 123456lifespan.org
                Author information
                https://orcid.org/0000-0002-8898-7406
                Article
                S0899823X2000286X
                10.1017/ice.2020.286
                7308630
                32517833
                c6e16fd1-6fc5-4941-a5ad-5608b3be119d
                © The Society for Healthcare Epidemiology of America 2020

                This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 01 June 2020
                : 06 June 2020
                Page count
                References: 18, Pages: 2
                Categories
                Commentary

                Comments

                Comment on this article